Sulfur Burps: Drugs That Cause or Treat Them

What sulfur burps actually are

Sulfur burps are eructation episodes with the characteristic rotten-egg odor of hydrogen sulfide gas. The gas forms when sulfate-reducing bacteria in the upper gastrointestinal tract metabolize sulfur-containing amino acids (methionine, cysteine) from food, or inorganic sulfate from certain medications and supplements. The symptom itself is a description of gas composition, not a diagnosis; it can arise from diet alone, from a medication effect, or from an underlying infection or motility disorder.

Hydrogen sulfide eructation results when sulfate-reducing gut bacteria outcompete other microbes for available substrate, a balance that dietary sulfur, altered gastric pH, slowed motility, and certain drugs can all shift. Established causes include high-sulfur diets, H. pylori infection, and small intestinal bacterial overgrowth; GLP-1 receptor agonists, metformin, and proton pump inhibitors are plausible drug-related contributors through gastric emptying and microbiome effects, though the exact frequency of sulfur burps (as distinct from general burping or GI upset) has not been separately measured in most drug trials. Persistent symptoms beyond several weeks, or symptoms with weight loss, dysphagia, or bleeding, should prompt medical evaluation rather than continued self-treatment.

Why this matters for people on GLP-1 medications or metformin

The most common reason a patient searches for this topic is that a new prescription, usually a GLP-1 agonist or metformin, was followed by an unpleasant new burping pattern. The useful clinical question is not simply "what makes the smell go away" but whether the timing and course of the symptom fits a self-limiting drug effect or instead points to something that needs its own workup, such as H. pylori or SIBO. Treating every case as "just the medication" risks missing a treatable infection; treating every case as an infection risks unnecessary testing when a slower dose titration would resolve it.

Drugs associated with sulfur burps

Multiple drug classes are associated with hydrogen sulfide-type burping through gastric motility or gut microbiome effects. The strength of evidence differs by class: some effects are documented on FDA labeling (delayed gastric emptying with GLP-1 agonists is a labeled pharmacodynamic effect), some are supported by observational research (PPI-SIBO association), and some are mechanistically plausible but not separately quantified for this specific symptom.

GLP-1 receptor agonists

Semaglutide, liraglutide, dulaglutide, and tirzepatide slow gastric emptying as part of their approved mechanism of action, which is how they promote satiety and blunt post-meal glucose rises. Slower emptying means food sits longer in contact with upper-GI bacteria, a mechanism that plausibly increases hydrogen sulfide formation. Pivotal obesity and diabetes trials for this class report that gastrointestinal adverse events, including nausea, diarrhea, and eructation, are common, generally affecting a substantial minority to roughly half of participants depending on dose and drug. Sulfur burps specifically are usually folded into the general "eructation" adverse-event category in trial reporting rather than tracked as their own outcome, so a precise incidence for the rotten-egg-specific symptom is not established. Readers and clinicians who need exact trial percentages should confirm them against the current FDA-approved prescribing information for the specific product, since labeling is updated periodically.

Metformin

Metformin causes gastrointestinal side effects, most often diarrhea, nausea, and bloating, in a meaningful proportion of new users; this is one of the best-established GI drug effects in general medicine. Extended-release formulations reduce but do not eliminate these effects. Metformin is also known to shift gut microbial composition as part of how it works, and it is biologically plausible that this shift includes sulfate-metabolizing organisms, but a direct, quantified link between metformin and sulfur-specific burping has not been separately established in the literature reviewed for this page. This distinction matters: the general GI side-effect profile of metformin is well documented; the sulfur-burp-specific mechanism is a reasonable inference, not a proven finding.

Proton pump inhibitors

Omeprazole, lansoprazole, pantoprazole, and similar PPIs suppress gastric acid and raise intragastric pH for much of the day. Observational research has linked long-term PPI use to increased risk of small intestinal bacterial overgrowth (SIBO), one of the more common identifiable causes of persistent sulfur burps. The exact magnitude of that risk varies across studies and should be confirmed against a current systematic review before quoting a specific number. For a patient with persistent sulfur burps on a long-term PPI, the practical question is whether the PPI indication still applies, since stepping down or discontinuing an unnecessary PPI is itself a treatment lever.

Antibiotics

Broad-spectrum antibiotics such as amoxicillin-clavulanate, clindamycin, and fluoroquinolones can disrupt normal gut flora and paradoxically allow sulfate-reducing bacteria to expand. This effect is typically described as starting several days into a course and potentially persisting for some weeks after the antibiotic is stopped, until normal flora recover. The exact duration of dysbiosis after a single course varies considerably between individuals and antibiotic classes.

Other medications with a plausible link

Sulfasalazine and mesalamine contain sulfur-based chemical groups and can directly add to luminal sulfate availability. Iron supplements slow colonic transit, which may extend bacterial fermentation time. Orlistat increases fat delivery to the colon, providing more substrate for bacterial fermentation generally. These are mechanistically reasonable associations rather than separately proven causal links to sulfur burps specifically.

Non-drug causes to rule out

Not every case traces back to a prescription. The differential includes dietary, infectious, and functional causes that should be considered before attributing the symptom entirely to a medication.

Dietary sulfur. Eggs, garlic, onions, cruciferous vegetables, red meat, and beer all supply sulfur-containing substrates to gut bacteria and can produce noticeable sulfur burps within hours of a heavy meal.

Helicobacter pylori infection. H. pylori colonizes the stomach in a large share of the world's population, with substantial regional variation in prevalence. Gastroenterology guidelines recommend testing for H. pylori in patients with unexplained dyspepsia, a category that includes persistent burping without another clear cause.

Small intestinal bacterial overgrowth (SIBO). SIBO involves excess bacterial populations in the small intestine and is typically diagnosed with lactulose or glucose hydrogen breath testing. Patients with SIBO commonly report sulfur burps alongside bloating and altered bowel habits.

Gastroparesis and other motility disorders. Delayed gastric emptying from diabetes, prior abdominal or vagal nerve surgery, or functional dyspepsia creates the same stagnant environment that favors hydrogen sulfide production, independent of any medication.

How the underlying cause gets diagnosed

Medication and diet review. Clinicians typically start by mapping the timing of symptom onset against any new medication or dose increase, and by asking about recent high-sulfur meals.

H. pylori testing. Non-invasive options include the urea breath test and the stool antigen test; serology is generally avoided for this purpose because it cannot distinguish an active infection from a past one.

Breath testing for SIBO. If medication and H. pylori are ruled out, hydrogen or hydrogen-methane breath testing after an overnight fast can identify bacterial overgrowth.

Gastric emptying study. When gastroparesis is suspected, particularly in long-standing diabetes or after abdominal surgery, a standardized scintigraphic gastric emptying study is the reference test.

This is a stepwise process best managed with a clinician; it is not something to self-diagnose from symptom pattern alone.

What actually helps

Bismuth subsalicylate

Bismuth subsalicylate (Pepto-Bismol) is the most directly evidence-supported over-the-counter option. Bismuth binds hydrogen sulfide in the gut, forming insoluble bismuth sulfide that is passed in stool (this also explains the harmless black stool some users notice). A controlled study in healthy volunteers found that bismuth subsalicylate substantially reduced fecal hydrogen sulfide release; the exact magnitude reported in that study should be verified against the primary paper before being quoted precisely in a clinical context. Standard OTC dosing information is on the product label; readers should follow label directions rather than an article's dosing suggestion, and should not use bismuth subsalicylate long-term without checking with a clinician, especially alongside aspirin-containing products or in kidney disease.

Addressing H. pylori

When testing is positive, guideline-recommended eradication regimens (commonly a proton pump inhibitor plus two or more antibiotics, or bismuth-based quadruple therapy, for about two weeks) resolve the infection in most patients and, with it, the associated dyspeptic symptoms. Regimen choice depends on local antibiotic resistance patterns and should be selected by the treating clinician, not from a general article.

Rifaximin for confirmed SIBO

Rifaximin is a non-absorbable antibiotic used for SIBO confirmed by breath testing. It is generally reserved for that confirmed diagnosis rather than used empirically for burping alone, and dosing and duration should be set by the prescribing clinician.

Slower GLP-1 titration and meal pacing

For sulfur burps that start after beginning or increasing a GLP-1 agonist, a slower dose-escalation schedule than the standard label minimum, done under the prescriber's guidance, along with smaller and more frequent meals, is a reasonable first step before assuming the medication must be stopped. This is site judgment and general clinical practice rather than a labeled instruction, and any change to a prescribed titration schedule should go through the prescribing clinician.

Simethicone, digestive enzymes, and probiotics

Simethicone reduces gas bubble surface tension but does not chemically neutralize hydrogen sulfide, so it may reduce burping volume without eliminating the odor. Alpha-galactosidase products target legume and vegetable oligosaccharides and have no direct sulfur-neutralizing effect. Probiotic strains that compete with sulfate-reducing bacteria have shown some benefit for general bloating and eructation symptoms in functional dyspepsia trials, but evidence specific to sulfur burps is limited. All three are low-risk and reasonable to try alongside, not instead of, addressing an identified cause.

Dietary sulfur reduction

A two-to-four-week trial reducing high-sulfur foods (eggs, cruciferous vegetables, alliums, red wine, dried fruit) can help clarify whether diet is the primary driver, with foods reintroduced one at a time afterward.

When to seek medical care rather than self-treat

Most sulfur burps are benign and improve with time or a targeted intervention. Seek prompt evaluation for unintentional weight loss, progressive difficulty swallowing, persistent vomiting, or black tarry stools not explained by bismuth use. New-onset sulfur burps after age 60, especially without an obvious dietary or medication trigger, is a reasonable indication to discuss upper endoscopy with a clinician to rule out ulcer disease or, rarely, malignancy.

If sulfur burps persist beyond roughly twelve weeks on a GLP-1 agonist despite slower titration and dietary adjustment, it is reasonable to pursue H. pylori testing and SIBO evaluation rather than continuing to attribute the symptom to the drug indefinitely. Switching from an injectable to an oral GLP-1 formulation is unlikely to help on its own, since the shared mechanism across the class is delayed gastric emptying, not the route of administration.

Evidence boundaries

Established: hydrogen sulfide eructation results from sulfate-reducing bacterial metabolism of sulfur substrates; GLP-1 agonists slow gastric emptying as a labeled pharmacodynamic effect; metformin causes GI side effects in a meaningful share of users; bismuth subsalicylate binds hydrogen sulfide; H. pylori and SIBO are recognized, treatable causes of chronic dyspeptic symptoms including burping.

Plausible but not separately proven: that metformin's microbiome effects specifically increase sulfur-burp frequency (rather than GI symptoms generally); the precise incidence of sulfur-smelling burps (as opposed to burping in general) on GLP-1 therapy; a specific numeric magnitude of PPI-associated SIBO risk.

Not established from the sources reviewed here: a validated timeline for when drug-induced sulfur burps resolve; a head-to-head comparison of which GLP-1 drug causes fewer sulfur burps; any claim that a specific probiotic strain reliably treats sulfur burps rather than general bloating.

Readers relying on precise trial statistics (percentages, odds ratios, eradication rates) mentioned in earlier versions of drug-safety content on this topic should confirm those figures against current FDA labeling, the relevant trial publication, or a current systematic review before treating them as settled numbers; several such figures could not be independently verified for this draft and have been described qualitatively instead.

Sulfur burp triage framework

Use the pattern of onset and course, not the smell itself, to decide what to do next.

Use this guide as a basis for discussing sulfur burps with your doctor, rather than as a replacement for professional diagnosis. Multiple causes can overlap, such as when dietary factors combine with medication side effects.

Quick drug reference

This article discusses medications and mechanisms for general education. It does not provide an individual diagnosis or dosing instructions; decisions about starting, stopping, or adjusting any prescription medication, including GLP-1 agonists, metformin, PPIs, or antibiotics for SIBO or H. pylori, should be made with the prescribing clinician.